Business Context and Reporting Period
This Form 8-K Current Report was filed by MRI Interventions, Inc. (Note: The request metadata lists "Clearpoint Neuro, Inc.", but the filing text identifies the registrant as MRI Interventions, Inc.) on December 21, 2015, regarding events occurring on December 18, 2015. The report details the completion of a private placement financing transaction.
Key Financial Metrics
- Gross Proceeds: Approximately $5.3 million received from the sale of units.
- Placement Fees: $380,155 in placement agents' fees.
- Units Sold: 16,309,270 units sold to accredited investors.
- Unit Composition: Each unit consists of one share of common stock, one Series A warrant (0.40 share), and one Series B warrant (0.30 share).
- Placement Agent Warrants: Approximately 1.6 million shares of common stock underlying warrants issued to placement agents.
Material Changes
The primary material change is the increase in equity capital and the expansion of the company's capital structure through the issuance of new common stock and warrants. This transaction was executed under exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Guidance, Outlook, and Contingencies
- Registration Rights: The Company is required to file a registration statement with the SEC by January 17, 2016, covering the resale of shares issued to investors and underlying warrants.
- Liquidated Damages: If the registration statement is not filed by the deadline, not declared effective by March 2, 2016 (or April 18, 2016 if reviewed), or if effectiveness is not maintained, the Company will incur liquidated damages to investors.
- Warrant Terms:
- Series A Warrants: Exercisable until December 18, 2020, at $0.4058 per share. Includes cashless exercise feature.
- Series B Warrants: Exercisable until December 18, 2020, at $0.5275 per share. Includes cashless exercise feature.
- Placement Agent Warrants: Exercisable until May 18, 2023, with terms similar to Series A.
Investor Verification Checklist
- Verify the exact net proceeds after deducting all offering expenses beyond the stated placement fees.
- Confirm the dilution impact of the 16.3 million new shares plus the potential issuance of warrants (Series A, Series B, and Placement Agent Warrants).
- Monitor the filing of the required Registration Statement by the January 17, 2016 deadline to avoid liquidated damages.
- Review the full text of the Securities Purchase Agreement and Registration Rights Agreement (Exhibits 10.1 and 10.2) for specific covenants and indemnification clauses.